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Abstract
Introduction: Iodine deficiency in pregnant women, even of a mild degree, may have adverse effects on both the mother and the foetus. 
Despite the obligatory model of functioning iodine prophylaxis in Poland, the iodine supply in women during pregnancy and physi-
ological lactation is insufficient. Therefore, those groups should take additional iodine supplementation at a dose of 150–200 µg/day. The 
aim of this study was to examine the effectiveness of iodine prophylaxis in pregnant women in Poland.
Material and methods: The assessment of iodine supply, urine iodine concentration (UIC) in the spot urine sample, as well as levels of 
TSH, fT4, thyroid antibodies, and thyroid volume, was performed at one time point in 115 women (7 in the 1st trimester, 61 in the 2nd 
trimester, and 47 in the 3rd trimester). 
Results: Only 45.2% of women were taking additional amounts of iodine at any time of pregnancy, and the median ioduria was 79.6 µg/L, 
which pointed to an insufficient supply of iodine. The percentage of women using iodine supplementation increased with the length of 
pregnancy, which indicates that the recommendations are implemented too late. In women who took iodine supplementation, ioduria 
was significantly higher than in those not applying iodine supplementation (median 129.4 µg/L vs. 73.0 µg/L; p < 0.001); however, this 
was still below recommended values.
Conclusions: The effectiveness of iodine prophylaxis in pregnant women in Poland, evaluated on the basis of the analysis of randomly 
chosen sample, is not satisfactory in terms of compliance with the recommendations and, possibly, the quality of supplementation. 
(Endokrynol Pol 2015; 66 (5): 404–411) 
Key words: iodine prophylaxis; pregnant women; iodine deficiency; ioduria
Streszczenie
Wstęp: Niedobór jodu u kobiet w ciąży, nawet łagodnego stopnia, może powodować niekorzystne następstwa zarówno u matki, jak 
i u płodu. Mimo obligatoryjnego modelu profilaktyki jodowej funkcjonującego w Polsce, podaż jodu u kobiet w okresie ciąży i fizjologicznej 
laktacji jest niewystarczająca. Dlatego osoby te powinny przyjmować dodatkową suplementację jodu w dawce 150–200 µg/dobę. Celem 
pracy była ocena skuteczności profilaktyki jodowej u kobiet w ciąży w Polsce na podstawie analizy podaży jodu oraz jodurii.
Materiał i metody: Oceniono w jednym punkcie czasowym podaż jodu, stężenie jodu w przygodnej próbce moczu, stężenia TSH, fT4 i prze-
ciwciał przeciwtarczycowych oraz ultrasonograficznie objętość tarczycy u 115 kobiet (7 w pierwszym trymestrze, 61 w drugim trymestrze oraz 
47 w trzecim trymestrze).
Wyniki: Tylko 45,2% kobiet przyjmowało dodatkowe ilości jodu, a mediana jodurii u wszystkich kobiet wyniosła 79,6 µg/l, co wskazuje na 
niedostateczną podaż jodu. Odsetek kobiet przyjmujących suplementację jodu wzrastał wraz z długością ciąży, co sugeruje, że rekomen-
dacje są wdrażane zbyt późno. U kobiet przyjmujących suplementację jodu, joduria była istotnie wyższa niż u kobiet nieprzyjmujących 
dodatkowych ilości jodu (mediana 129,4 µg/l vs. 73,0 µg/l; p < 0,001), jednak wartości te wciąż były niższe niż rekomendowane. 
Wnioski: Skuteczność profilaktyki jodowej u kobiet w ciąży w Polsce, oceniona na podstawie analizy przekrojowej przypadkowo 
wybranych osób, nie jest zadowalająca pod względem przestrzegania zaleceń, i prawdopobnie, jakości prowadzonej suplementacji. 
(Endokrynol Pol 2015; 66 (5): 404–411)
Słowa kluczowe: profilaktyka jodowa; kobiety w ciąży; niedobór jodu; joduria
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comprehension than were those of mothers with a ra-
tio of 150 µg/g or more. These results were even worse 
when the ioduria was below 50 µg/g [15]. In a recently 
performed study in the Netherlands, classified as an 
iodine-sufficient area, an association between low ma-
ternal urinary iodine and impaired executive function 
in offspring has been revealed [16]. In contrast, Ghas-
sabian et al. [17] found no relation between maternal 
urine iodine concentration (UIC) in early pregnancy 
and children’s language comprehension at 6 years.
Despite the methodological difficulties of capturing 
the relationship between the iodine supplementation 
and cognitive function in children, the obtained data 
show the importance of optimal iodine intake during 
early gestation and emphasise the risk that mild iodine 
deficiency can pose to the developing infant, even in 
areas classified as iodine sufficient.
The current model of iodine prophylaxis in Poland 
was developed by the Polish Council for Control of Iodine 
Deficiency Disorders (PCCIDD) [18] and contains 
obligatory iodisation of household salt (20–40 mg KI/1 kg), 
neonates’ formula (10 µg/100 mL of milk), and addi-
tional supplementation for pregnant and breastfeeding 
women with 150–200 µg of iodine [18].
As in other countries, as well as in Poland, both iodine 
compounds, i.e. KI and KIO3, are used [19], although 
ongoing experiments have created certain controversies 
in terms of the safety of the latter iodine carrier [20, 21].
The effectiveness of iodine prophylaxis in Poland 
conducted since 1997 has been confirmed in a number 
of studies [22–25]. The results were quite satisfactory, 
especially when the incidence of goitre in children 
(37.5% vs. 1.4%) or median value of ioduria (45.2 vs. 
101.1 µg/L) observed before and after the introduction 
of prophylaxis were compared [26].
However, there was some concern over the fact that 
the above ioduria levels, although remaining in refer-
ence ranges, oscillated around the borderline values 
[26], which in the case of dietary salt restriction may 
again lead to too little iodine intake. 
The World Health Organisation (WHO) has issued 
a recommendation that increased salt consumption, as 
a risk factor for hypertension, atherosclerosis, myocar-
dial infarction, and stroke, should be restricted [27, 28].
Reducing the amount of sodium in a diet (below 
5 g/day) is one of the main recommendations for life-
style modification in patients with hypertension [29], 
but the European Society of Hypertension and the 
European Society of Cardiology recommend salt intake 
of 5–6 g/day even in the general population [30]. The 
arguments for limiting salt intake in the diet are so 
numerous and consistent that in the coming years we 
should expect a significant (reaching as high as 70%) 
decrease in salt intake in the Polish population [31]. 
Introduction
Iodine is an essential micronutrient required for thy-
roid hormone synthesis. Thyroid hormones not only 
ensure the proper functioning of the body, but during 
foetal life and childhood they are also responsible for 
the proper development of the whole organism, the 
nervous system included [1, 2].
It is documented that iodine deficiency, especially 
when severe, is one of the most significant, preventable 
causes of mental retardation in the world [3]. Therefore, 
the elimination of iodine deficiency has been the aim 
of actions undertaken by international communities in 
recent years [4]. Each country should conduct iodine 
prophylaxis based on the model, which should be 
developed taking into account its individual circum-
stances. The most common and relatively inexpensive 
way of conducting iodine prophylaxis is the use of 
iodised salt — mandatory or optional [5]. Thanks to 
iodine prophylaxis, severe iodine deficiency is now less 
and less common [6]. In contrast, mild-to-moderate io-
dine deficiency is still considered a major public health 
concern, even in some developed countries [7].
Pregnant women are particularly susceptible to 
iodine deficiency because of the higher requirement 
during pregnancy [8]. Thyroid hormone synthesis and 
daily iodine intake increase by approximately 50% in 
the first few weeks of pregnancy [9]. 
Therefore, guidelines recommend an almost twofold 
increase in dietary iodine intake during pregnancy to 
maintain optimal thyroid hormone synthesis in the 
mother and the foetus [10–12]. In accordance with the 
recommendations adopted in Poland, pregnant and 
lactating women should receive iodine supplementa-
tion at a dose of 150–200 µg of iodine/day [12]. Due to 
the fact that the significantly increased demand for 
iodine occurs in the first trimester of pregnancy, it is 
postulated that iodine supplementation should begin 
several months before conception [12]. It was calculated 
by Zimmermann [13] that the total iodine amount of 
220–250 µg/day consumed by pregnant women corre-
sponds to a urine iodine concentration of 135–150 µg/L. 
Nevertheless, the total iodine supply during pregnancy 
should be at least 250 µg daily [10–12].
Although severe iodine deficiency in pregnancy is well 
known to result in adverse childhood outcomes, such as 
cretinism and mental retardation [13], less is known about 
the effects of mild-to-moderate deficiency [14].
For example, Bath et al. [15] assessed the associa-
tion between maternal iodine status and child IQ at 
age 8 years and reading ability at age 9 years. Children 
of mothers with ioduria below 150 µg/g (iodine to 
creatinine ratio) were more likely to be in the smallest 
quartile for verbal IQ, reading accuracy, and reading 
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The aim of the study was to examine the effective-
ness of iodine prophylaxis in pregnant women by 
evaluating the supply of iodine and ioduria. 
Material and methods
The study included 115 women, patients of the Out-
patient Gynaecological Department of the Polish 
Mother’s Memorial Hospital — Research Institute in 
Lodz. Women came to the outpatient department in 
order to receive maternity care in mid-2010. None of 
the subjects had been ever been treated for thyroid 
disease and had never remained under the care of an 
endocrinologist. The examined women had only stayed 
under gynaecological care.
During the study, the patients were asked about 
medications, including preparations containing iodine, 
and their eating habits. A spot urine sample was secured 
for determination of iodide concentration. Samples 
were stored at –70o C until assay. In order to determine 
iodide concentration, the modified catalytic method 
by Sandell and Kolthoff was used [32]. A blood sam-
ple was drawn from each patient to measure the free 
thyroxine (fT4), TSH, and thyroid antibodies (antiTPO, 
antiTg, antiTSHR). Quantitative analyses of hormones 
and antibodies were performed by chemiluminescent 
immunoassays using a Roche Diagnostics automatic 
analyser — Cobas. Normal ranges for the analysed data 
were: TSH 0.27–4.2 mIU/L, fT4 0.93–1.7 ng/dL, antiTPO 
< 34.0 IU/mL; antiTg < 115 IU/mL and antiTSHR 
< 1.8 IU/L. 
Thyroid palpation was performed, followed by 
ultrasound examination of the thyroid gland with 
a Toshiba Aplio XG (Toshiba Medical Systems Corpo-
ration, Japan) with a 12 MHz linear transducer (model 
PLT-1204BT, Toshiba Medical Systems Corporation, 
Japan). Measurements were performed while the 
subjects were lying on a medical coach. The sum 
of lateral thyroid lobe volumes constituted the ac-
tual volume of the thyroid gland; the volume of the 
isthmus was skipped. The volume of thyroid lobe 
was calculated according to the following formula, 
proposed by Brunn et al. [33]: 
V [mL] = 0.479 × W × D × L
where: W — width [cm]; D — depth [cm]; L — 
length [cm].
Neonates’ TSH was examined as part of the neo-
natal screening protocol. The procedure was based on 
determination of TSH in dried blood spots obtained 
by heel puncture three days after birth. Values above 
15 mIU/L were indicative of hypothyroidism.
Patients have given their consent to the study, 
voluntarily signing the appropriate statement. The 
Ethical Committee approved the protocol (“Thyro-
Mobil Project”). The study was part of a program 
on iodine deficiency in pregnant women. The basic 
characteristics of the studied population are shown 
in Table I.
The data were statistically analysed using non-
parametric test for independent groups (Mann-Whitney 
Rank Sum test), Kruskal-Wallis One Way Analysis of 
Variance on Ranks, followed by Dunn test and Chi-
Square analysis. In all analyses, statistical significance 
was accepted at the level of p < 0.05. Data processing, 
statistical analyses, and figures were performed by using 
SigmaPlot 12.3 (Systat Software, Inc., San Jose, CA, USA) 
and Excel (Microsoft Corp., Redmond, WA, USA).
Results
Median ioduria among the surveyed women, indepen-
dently of the time point of measurement, was 79.6 µg/L, 
which corresponds to iodine deficiency. In the differ-
ent trimesters of pregnancy, these values were similar 
and equalled in the first trimester — 80.1 µg/L, in the 
second trimester — 81.3 µg/L, and in the third trimester 
— 78.4 µg/L. The UIC values in different trimesters of 
pregnancy are presented in Figure 1.
Only 45.2% of women were taking iodine supple-
mentation at any time during pregnancy. Iodine 
prophylaxis was based on multivitamin supplements 
containing iodine prepared for pregnant women. None 
of the women received pure KI. The number of subjects 
taking iodine supplementation varied in particular 
trimesters: in the first trimester — none of the subjects; 
in the second trimester — 15 subjects from the group of 
61 patients (24.6%); in the third trimester — 37 subjects 
from the group of 47 patients (78.7%). Figure 2 shows 
the percentage distribution of women taking iodine 
supplementation. 
Iodine supplementation given to 52 women from the 
group of 115 women (45.2%) contributed to an increase 
of ioduria in comparison to the group of women not tak-
ing iodine supplementation (median 129.4 µg/L vs. 73.0 
µg/L; p < 0.001); however, the median value of ioduria 
Table I. The number and age of the women examined in 
different trimesters
Tabela I. Liczba i wiek przebadanych kobiet w poszczególnych 
trymestrach ciąży
n Age
Mean ± SD Min. Max.
I trimester 7 28.6 ± 5.3 22 39
II trimester 61 28.6 ± 4.7 18 37
III trimester 47 29.4 ± 4.9 18 39
Total 115 29.2 ± 4.6 18 39
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still did not reach the recommended level. Figure 3 
shows the ioduria in women taking iodine supplemen-
tation and in those with no iodine supplementation. 
Among women taking iodine supplementation, 
only in the second trimester, the median ioduria was 
higher than 135–150 µg/L and equalled 167.8 µg/L. 
Figure 4 depicts the values of ioduria in the group 
receiving iodine supplementation and in the group 
without iodine supplementation in different trimes-
ters of pregnancy.
Table II presents the values of UIC, TSH, fT4, antithy-
roid antibodies concentrations, and thyroid volume. 
The values of TSH, fT4, anti-Tg, anti-TPO, and anti-
TSHR concentrations did not differ between groups. 
TSH and fT4 values remained in normal ranges in all 
subjects. Anti-Tg antibodies were increased in two 
women in the first trimester. Anti-Tg and anti-TPO 
antibodies were increased in one and two subjects, 
respectively, in the second trimester; and in one and 
five subjects, respectively, in the third trimester of 
pregnancy. None of them had increased concentra-
tion of anti-TSHR. The thyroid volumes did not differ 
between groups. Seven subjects were diagnosed by 
ultrasonography as having a goitre (three women in 
II trimester and four women in III trimester).
20 100
[%]
Yes No
I trymestr
II trymestr
III trymestr
Total
40 8060
n = 0
n = 15
n = 37
n = 52
24.6
78.7
45.2
0
Figure 2. The frequency of women taking iodine supplementation 
anytime during pregnancy
Rycina 2. Odsetek kobiet przyjmujących suplementację jodu 
w czasie badania
Figure 3. The dependence of urinary iodine concentration (UIC) 
in pregnant women on iodine supplementation. Upper and lower 
limits of boxes are 75 and 25 percentiles, respectively. Horizontal 
solid line and dotted line in the boxes are median and mean, 
respectively. Whiskers mean standard deviation (SD). Points are 
scatter of UIC. Horizontal long solid line and dashed line indicate 
lowest normal values of UIC for pregnant women, which are 
150 µg/L and 135 µg/L, respectively
Rycina 3. Stężenie jodu w moczu (UIC) u kobiet w ciąży 
w zależności od przyjmowania suplementacji jodu. Górne i dolne 
krawędzie prostokątów odpowiadają wartościom odpowiednio 
75 i 25 percentyla. Poprzeczne linie ciągłe oraz kropkowane 
wewnątrz prostokątów oznaczają odpowiednio wartości mediany 
i średniej. Wąsy odpowiadają odchyleniom standardowym. Punkty 
stanowią rozrzut stężeń jodu w moczu. Poprzeczna długa linia 
ciągła i przerywana wskazują na dolne wartości prawidłowe 
stężenia jodu w moczu u kobiet w ciąży, odpowiednio 150 µg/l 
i 135 µg/l
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Figure 1. Urinary iodine concentration (UIC) in the examined 
pregnant women in different trimesters. Upper and lower limits 
of boxes are 75 and 25 percentiles, respectively. Horizontal solid 
line and dotted line in the boxes are median and mean, respectively. 
Whiskers mean standard deviation (SD). Points are scatter of 
UIC. Horizontal long solid line and dashed line indicate lowest 
normal values of UIC for pregnant women, which are 150 µg/L and 
135 µg/L, respectively
Rycina 1. Stężenie jodu w moczu (UIC) u badanych kobiet 
w poszczególnych trymestrach. Górne i dolne krawędzie 
prostokątów odpowiadają wartościom odpowiednio 75 i 25 
percentyla. Poprzeczne linie ciągłe oraz kropkowane wewnątrz 
prostokątów oznaczają odpowiednio wartości mediany 
i średniej. Wąsy odpowiadają odchyleniom standardowym. 
Punkty stanowią rozrzut stężeń jodu w moczu. Poprzeczna 
długa linia ciągła i przerywana wskazują na graniczne 
wartości prawidłowe stężenia jodu w moczu u kobiet w ciąży, 
odpowiednio 150 µg/l i 135 µg/l
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The results of neonates’ TSH were obtained in 
92 cases. All the results were within normal limits. The 
median of neonates’ TSH was 1.36 mIU/L and the mean 
± SD was 1.55 ± 1.19. Only in two subjects, the TSH 
value was above 5 mIU/L (5.69; 7.79). 
Discussion
The introduction of the current model of iodine prophy-
laxis has been proven to be very successful. The supply 
of iodine in the Polish population has significantly in-
creased and has reached normal values. However, the 
amount of iodine added to kitchen salt (30 mg of KI or 
39 mg of KIO3/kg NaCl [19]) does not provide optimal 
iodine intake during pregnancy and in breast-feeding 
women, in whom the need for iodine is greater than 
in the general population. Thus, iodine prophylaxis 
in these individuals, carried out only on the basis of 
mandatory consumption of iodised kitchen salt, is insuf-
ficient, and they should receive an additional amount Ta
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Figure 4. The dependence of urinary iodine concentration 
(UIC) in pregnant women in different trimesters on iodine 
supplementation. Upper and lower limits of boxes are 75 and 25 
percentiles, respectively. Horizontal solid line and dotted line 
in the boxes are median and mean, respectively. Whiskers mean 
standard deviation (SD). Points are scatter of UIC. Horizontal 
long solid line and dashed line indicate lowest normal values 
of UIC for pregnant women, which are 150 µg/L and 135 µg/L, 
respectively
Rycina 4. Stężenie jodu w moczu (UIC) u kobiet w ciąży 
w poszczególnych trymestrach ciąży w zależności od suplementacji 
jodu. Górne i dolne krawędzie prostokątów odpowiadają 
wartościom odpowiednio 75 i 25 percentyla. Poprzeczne linie ciągłe 
oraz kropkowane wewnątrz prostokątów oznaczają odpowiednio 
wartości mediany i średniej. Wąsy odpowiadają odchyleniom 
standardowym. Punkty stanowią rozrzut stężeń jodu w moczu. 
Poprzeczna długa linia ciągła i przerywana wskazują na graniczne 
wartości prawidłowe stężenia jodu w moczu u kobiet w ciąży tj. 
odpowiednio 150 µg/l i 135 µg/l
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of iodine (150–200 µg/day) in the form of multivitamin 
tablets containing iodine or in the form of pure KI [12] .
Unfortunately, our data indicate that less than half 
of the women (45.2%) followed those recommendations 
and received an additional amount of iodine. Similar 
data were obtained by Gietka-Czernel et al. and by 
Milewicz et al., who performed studies in women liv-
ing around Warsaw and Krakow, respectively [34, 35]. It 
should, however, be emphasised that the recommenda-
tions are directed at physicians, not at patients. Thus, 
the relatively small percentage of women who take the 
iodine supplementation is mainly due to doctors’ orders 
that deviate significantly from the recommendations. It 
should be noted that the proportion of women receiving 
iodine supplementation increases with advancement of 
pregnancy, and in the third trimester it reaches 78.7%. 
It can therefore be concluded that the majority of phy-
sicians supplement optimal iodine intake in pregnant 
women, but only in the third trimester of pregnancy. 
In the first and second trimesters, the proportion of 
women taking iodine supplementation is very low 
(0% and 24.6%, respectively). Such observations are 
obviously unsatisfactory, since it is the early period 
of pregnancy when the foetus is particularly sensitive 
to iodine deficiency, due to the developing nervous 
system. Taking into account the increased demand for 
iodine in pregnant women, the above observations as 
well as our findings additionally confirm the notion 
that iodine supplementation should start in the pre-
conception period. 
It is worth noting that the median ioduria in women 
taking iodine supplementation has not reached the 
recommended values (median 129.4 µg/L vs. at least 
135–150 µg/L), which means that, despite the conducted 
prevention, iodine supply was insufficient. These values 
are similar to the data observed by other authors. For 
example, among pregnant women in whom the iodine 
supplementation was conducted, a median ioduria was 
found at the level of 96 µg/L (I trimester), 122 µg/L (II 
trimester), and 129 µg/L (III trimester) [36]. The question 
therefore arises whether the recommended additional 
dose of iodine (150–200 µg/L) is not too low. It is very 
difficult to answer this question, but in the deliberations 
on this issue it should be taken into account that a lot 
of preparations containing iodine are not registered as 
drugs but as dietary supplements, which may translate 
into differences between the claimed concentrations of 
iodine in the medicament dose and the measured ones. 
Restani et al. [37] investigated 43 preparations contain-
ing iodine, and in most cases the actual amount of 
iodine was different from the declared amount. It should 
also be noted that some multivitamins do not contain 
iodine, and because of the similarity of names they may 
be mistakenly taken [this applies to “over-the-counter” 
(OTC) medications]. Also another issue should be taken 
into account. Namely, during pregnancy, as a result of 
physiological changes that occur in a woman’s body, 
the amount of excreted urine increases, and therefore 
it would be more reasonable to compare ioduria in 
pregnant women in relation to creatinine excretion. In-
teresting observations were made by Gowachirapant et 
al. [38], who measured ioduria in school-aged children 
and their mothers being pregnant at the time of the 
study; these families lived together and had a similar 
diet. They noted that ioduria in children was correct; 
while in pregnant women it indicated a deficiency of 
iodine in the diet.
Taking into account the obtained values of ioduria, 
further diversification of iodine supply should also be 
considered, especially in the context of actions taken 
to reduce the consumption of salt. Various kinds of 
mineral water and milk, enriched in iodine during the 
production process, should be remembered here. Rec-
ommendations on drinking water and milk containing 
Table III. Characteristics of studies on the use of iodine prophylaxis in pregnant women in Poland
Tabela III. Charakterystyka prac na temat stosowania profilaktyki jodowej u kobiet w ciąży w Polsce
City/Region of Poland Number of subjects (n) Median of UIC [µg/L] Percentage of women taking 
iodine supplementation (%)
Type of analysis
Warsaw [36] 62 I — 98
II — 122
III — 129
100% Prospective study
Krakow Region [35] 500 n/d 59% Questionnaire analysis
Warsaw (Central Poland) [34] 100 112.6 35% Cross-sectional study
Lodz (Central Poland) 115 I — 80.1
II — 81.3
III — 78.4
I — 0%
II — 24.6%
III — 78.7%
Cross-sectional study
UIC — urinary iodine concentration
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iodine in the concentration of 150–200 µg/L could even 
better protect the foetus and the mother from iodine 
deficiency and from the risk of overdose [39].
Our work was not a prospective study, and hence 
the number of subjects in each group is not compara-
ble. This difference is due to the fact that the centre 
in which the research was conducted is a centre with 
a higher degree of referentiality. However, we believe 
that such a method of analysis allowed us to capture 
the actual state of iodine intake and, to a certain extent, 
the quality of iodine prophylaxis. Whereas prospective 
studies are usually treated as more informative, the 
performed cross-sectional analysis in the present study 
does constitute the only objective method to evaluate 
the real effectiveness of iodine prophylaxis in pregnant 
women in Poland.
Table III presents the basic data of studies on the use 
of iodine prophylaxis in Poland. 
Conclusions
Based on the obtained results it can be concluded that:
1. A significant percentage of pregnant women in 
Poland do not fulfil the criteria of iodine sufficiency.
2. Not all pregnant women, especially at the begin-
ning of pregnancy, take the recommended iodine 
supplementation, which suggests that more 
effective actions should be undertaken to promote 
iodine supplementation pre-conception and during 
pregnancy.
3. Iodine deficiency is seen even in a certain percent-
age of pregnant women who declare that they take 
iodine supplements, which suggests that the qual-
ity of the supplementation should be also verified.
Thus, the general conclusion is that the effectiveness 
of iodine prophylaxis in pregnant women in Poland, 
evaluated on the basis of the analysis of a randomly 
chosen sample, is not satisfactory in terms of compli-
ance with the recommendations and, possibly, the 
quality of the supplementation.
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